These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 23204065)
1. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Bajwah S; Ross JR; Peacock JL; Higginson IJ; Wells AU; Patel AS; Koffman J; Riley J Thorax; 2013 Sep; 68(9):867-79. PubMed ID: 23204065 [TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of sildenafil in interstitial pneumonia with pulmonary hypertension]. Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K Nihon Kokyuki Gakkai Zasshi; 2011 Mar; 49(3):151-5. PubMed ID: 21485145 [TBL] [Abstract][Full Text] [Related]
4. Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success. Brunetti G; Malovini A; Maniscalco M; Balestrino A; Carone M; Visca D; Capelli A; Vitacca M; Bellazzi R; Piaggi G; Fuschillo S; Aliani M; Spanevello A; Prince I; Paneroni M; Ambrosino N Respir Med; 2021; 185():106473. PubMed ID: 34038844 [TBL] [Abstract][Full Text] [Related]
5. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Holland AE; Hill CJ; Glaspole I; Goh N; McDonald CF Respir Med; 2012 Mar; 106(3):429-35. PubMed ID: 22182340 [TBL] [Abstract][Full Text] [Related]
6. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
7. Current approaches to the management of idiopathic pulmonary fibrosis. Raghu G; Richeldi L Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832 [TBL] [Abstract][Full Text] [Related]
8. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Corte TJ; Gatzoulis MA; Parfitt L; Harries C; Wells AU; Wort SJ Respirology; 2010 Nov; 15(8):1226-32. PubMed ID: 20920139 [TBL] [Abstract][Full Text] [Related]
9. Sildenafil in idiopathic pulmonary fibrosis. Mubarak K N Engl J Med; 2010 Nov; 363(22):2170; author reply 2170-1. PubMed ID: 21105802 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Wang RC; Jiang FM; Zheng QL; Li CT; Peng XY; He CY; Luo J; Liang ZA Respir Med; 2014 Mar; 108(3):531-7. PubMed ID: 24462476 [TBL] [Abstract][Full Text] [Related]
11. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Nathan SD; du Bois RM; Albera C; Bradford WZ; Costabel U; Kartashov A; Noble PW; Sahn SA; Valeyre D; Weycker D; King TE Respir Med; 2015 Jul; 109(7):914-22. PubMed ID: 25956020 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Pulmonary Rehabilitation in Interstitial Lung Disease, Including Coronavirus Diseases: A Systematic Review and Meta-analysis. Reina-Gutiérrez S; Torres-Costoso A; Martínez-Vizcaíno V; Núñez de Arenas-Arroyo S; Fernández-Rodríguez R; Pozuelo-Carrascosa DP Arch Phys Med Rehabil; 2021 Oct; 102(10):1989-1997.e3. PubMed ID: 33932361 [TBL] [Abstract][Full Text] [Related]
13. Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors. Anand A; Srivastava N; Barwad P; Ramakrishnan S; Roy A; Bhargava B Int J Cardiol; 2014 Jul; 174(3):574-8. PubMed ID: 24820738 [TBL] [Abstract][Full Text] [Related]
14. Palliative care for people with non-malignant lung disease: summary of current evidence and future direction. Boland J; Martin J; Wells AU; Ross JR Palliat Med; 2013 Oct; 27(9):811-6. PubMed ID: 23838376 [TBL] [Abstract][Full Text] [Related]
15. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Huppmann P; Sczepanski B; Boensch M; Winterkamp S; Schönheit-Kenn U; Neurohr C; Behr J; Kenn K Eur Respir J; 2013 Aug; 42(2):444-53. PubMed ID: 23100507 [TBL] [Abstract][Full Text] [Related]
16. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Collard HR; Anstrom KJ; Schwarz MI; Zisman DA Chest; 2007 Mar; 131(3):897-899. PubMed ID: 17356110 [TBL] [Abstract][Full Text] [Related]
17. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Gilbert C; Brown MCJ; Cappelleri JC; Carlsson M; McKenna SP Chest; 2009 Jan; 135(1):137-142. PubMed ID: 18812447 [TBL] [Abstract][Full Text] [Related]
18. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. Mercurio V; Carlomagno G; Fazio S Heart Lung; 2012; 41(5):512-7. PubMed ID: 22054725 [TBL] [Abstract][Full Text] [Related]
19. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Holland AE; Hill CJ; Conron M; Munro P; McDonald CF Thorax; 2008 Jun; 63(6):549-54. PubMed ID: 18245143 [TBL] [Abstract][Full Text] [Related]
20. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Swigris JJ; Streiner DL; Brown KK; Belkin A; Green KE; Wamboldt FS; Respir Med; 2014 Jan; 108(1):181-8. PubMed ID: 24388667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]